Evidence map›Paper›PMID 33459126›Full record

ArticleRenal failure2021

Relationship between doses of antihypertensive drugs and left ventricular mass index changes in hemodialysis patients in a Japanese cohort.

Fumiya Kitamura, Makoto Yamaguchi, Takayuki Katsuno, Hironobu Nobata, Shiho Iwagaitsu, Hirokazu Sugiyama, Hiroshi Kinashi, Shogo Banno, Masahiko Ando, Yoko Kubo and 5 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Fumiya KitamuraDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Makoto YamaguchiDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Takayuki KatsunoDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Hironobu NobataDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Shiho IwagaitsuDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Hirokazu SugiyamaDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Hiroshi KinashiDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Shogo BannoDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Masahiko AndoData Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Yoko KuboDepartment of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasumasa KawadeSuzuka Kidney Clinic, Josuikai Group, Suzuka, Japan.
Iwashima ShigejiroSuzuka Kidney Clinic, Josuikai Group, Suzuka, Japan.
Yutaka ItoYokkaichi Kidney Clinic, Josuikai Group, Yokkaichi, Japan.
Takuji IshimotoDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiko ItoDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Aichi Medical University · JPYokkaichi University · JPSuzuka University · JPNagoya University · JPNagoya University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Left ventricular hypertrophy commonly occurs in dialysis patients and is associated with a risk of developing cardiovascular disease events and all-cause mortality. Although hypertension treatment reduces left ventricular mass index (LVMI) in hemodialysis patients, the relationships of prescription pattern, dose, and changes in the dose of antihypertensive drugs with LVMI have not been completely elucidated. Here, we hypothesized that volume reduction would lead to a decrease in the antihypertensive drug dose and subsequently to a reduction in LVMI; conversely, fluid retention would lead to an increase in the antihypertensive drug use and, subsequently, to LVMI progression. To assess this hypothesis, we investigated the relationship between changes in the dose of antihypertensive drugs and subsequent changes in LVMI in 240 patients who had just started hemodialysis using a retrospective hemodialysis cohort in Japan. Using multiple linear regression analysis, we assessed the association between changes in the antihypertensive drug dose over 1 year after hemodialysis initiation and changes in LVMI during this period. A decrease and an increase in the antihypertensive drug dose were significantly associated with a reduction in LVMI (vs. no change; β  = - 17.386,

Indexed as

AgedAntihypertensive AgentsBlood PressureDose-Response Relationship, DrugEchocardiographyFemaleHumansHypertrophy, Left VentricularJapanKidney Failure, ChronicLinear ModelsMaleMiddle AgedRenal DialysisRetrospective StudiesAntihypertensive AgentsAntihypertensivecardiovascular diseasehemodialysisleft ventricular mass index

Identifiers

PMID33459126
PMCPMC7833083
OpenAlexW3124799636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.